More News! 28 Feb 2018 Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease? Polish researchers tested a new variant of CRISPR/Cas9 that increases the gene-editing system’s precision in targeting specific DNA sequences, such as the gene responsible for Huntington’s disease. CRISPR/Cas9 offers a means of editing genes by essentially ‘cutting and pasting’ sequences of DNA. A group of researchers at the Institute of Bioorganic Chemistry in Poland has developed […] February 28, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2018 Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical company dedicated to women’s reproductive medicine, states that current Phase III results for the drug show an increase in pregnancy rate of 32 % after […] February 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2018 AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and efficiency of drug development. Pelago, a Karolinska Institute spin-off, studies the interactions between a drug and its target to make the drug development process faster and more efficient. The Cellular Thermal Shift Assay (CETSA) was developed by Pelago to examine the […] February 26, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2018 ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After raising €9.4M in January, ASIT Biotech has now brought the amount raised on the Euronext Brussels stock up to €13.9M. The funds will be put towards the Phase III […] February 26, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2018 Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug. After obtaining approval for an injected version, Novo Nordisk is now getting ready […] February 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2018 You Will Soon Be Able To Paint With Bacteria! Researchers in the UK and the Netherlands have unlocked the genetic code that changes the color of certain bacteria. The discovery could lead to large-scale manufacturing of biodegradable, non-toxic paint. In a collaborative study between the University of Cambridge and the Dutch company Hoekmine, researchers compared the genetic information of certain bacterial colonies to their […] February 22, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2018 FDA Approves AstraZeneca’s Lung Cancer Treatment after Rejecting Merck and Pfizer’s The FDA approval will give AstraZeneca a competitive advantage in the lung cancer treatment market over Merck KGaA & Pfizer, who received rejections for a similar treatment. AstraZeneca received FDA approval for Imfinzi in non-small cell lung cancer one day after Merck KgA and Pfizer received a rejection for competitor drug Bavencio in the same indication. Imfinzi (durvalumab) […] February 21, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2018 Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment Phase I results show promise for a new treatment for atopic dermatitis that may become a strong competitor to the market leader, Humira. Morphosys and Galapagos are developing an antibody that could compete with the world’s best selling drug, Humira. The team announced details on positive results of a Phase I trial for treating atopic dermatitis […] February 20, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email